MX2017002085A - Tratamientos con nanopartículas núcleo-corteza de proteína/oligonucleótido. - Google Patents

Tratamientos con nanopartículas núcleo-corteza de proteína/oligonucleótido.

Info

Publication number
MX2017002085A
MX2017002085A MX2017002085A MX2017002085A MX2017002085A MX 2017002085 A MX2017002085 A MX 2017002085A MX 2017002085 A MX2017002085 A MX 2017002085A MX 2017002085 A MX2017002085 A MX 2017002085A MX 2017002085 A MX2017002085 A MX 2017002085A
Authority
MX
Mexico
Prior art keywords
protein
shell nanoparticle
core
nanoparticle therapeutics
oligonucleotide core
Prior art date
Application number
MX2017002085A
Other languages
English (en)
Inventor
A Mirkin Chad
D Brodin Jeffrey
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of MX2017002085A publication Critical patent/MX2017002085A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/02—Monosaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P3/00—Preparation of elements or inorganic compounds except carbon dioxide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

La presente descripción se refiere a nanopartículas núcleo-corteza, composiciones que comprenden nanopartículas núcleo-corteza, y métodos para su uso.
MX2017002085A 2014-08-19 2015-08-19 Tratamientos con nanopartículas núcleo-corteza de proteína/oligonucleótido. MX2017002085A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462039340P 2014-08-19 2014-08-19
US201462039608P 2014-08-20 2014-08-20
US201562137183P 2015-03-23 2015-03-23
PCT/US2015/045971 WO2016028940A1 (en) 2014-08-19 2015-08-19 Protein/oligonucleotide core-shell nanoparticle therapeutics

Publications (1)

Publication Number Publication Date
MX2017002085A true MX2017002085A (es) 2017-08-21

Family

ID=55351241

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002085A MX2017002085A (es) 2014-08-19 2015-08-19 Tratamientos con nanopartículas núcleo-corteza de proteína/oligonucleótido.

Country Status (8)

Country Link
US (1) US12264344B2 (es)
EP (1) EP3183007B1 (es)
JP (1) JP6797108B2 (es)
CN (2) CN106794256B (es)
AU (3) AU2015305482B2 (es)
CA (1) CA2958431A1 (es)
MX (1) MX2017002085A (es)
WO (1) WO2016028940A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3452598A4 (en) 2016-05-06 2020-04-29 Exicure, Inc. LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
CN108148758B (zh) * 2016-12-05 2021-09-17 中国科学院大连化学物理研究所 一种绒毛外滋养细胞纳米颗粒暴露的体外模型建立方法
US11491231B2 (en) * 2017-03-31 2022-11-08 University of Pittsburgh—of the Commonwealth System of Higher Education Peptide-oligonucleotide chimeras (POCs) as programmable biomolecular constructs for the assembly of morphologically-tunable soft materials
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
US10973927B2 (en) 2017-08-28 2021-04-13 The Chinese University Of Hong Kong Materials and methods for effective in vivo delivery of DNA nanostructures to atherosclerotic plaques
WO2020077060A1 (en) * 2018-10-10 2020-04-16 University Of Washington High-polymer-density bioconjugate compositions and related methods
EP3820454A4 (en) 2018-11-07 2023-03-15 University of Notre Dame du Lac PHAGEN MIMICANT NANOPARTICLES
US20210332495A1 (en) * 2018-12-06 2021-10-28 Northwestern University Protein Crystal Engineering Through DNA Hybridization Interactions
USD982375S1 (en) 2019-06-06 2023-04-04 Sharkninja Operating Llc Food preparation device
CN110531061B (zh) * 2019-07-11 2022-06-28 宁波大学 一种基于核壳纳米材料的肿瘤标志物可循环免疫检测方法
WO2021054407A1 (ja) * 2019-09-18 2021-03-25 国立大学法人九州大学 導入装置、高分子の細胞導入方法、ｄｎａナノ粒子結晶及びｄｎａナノ粒子結晶封入体の製造方法
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
US20210220454A1 (en) * 2020-01-22 2021-07-22 Northwestern University Design of immunostimulatory protein-core spherical nucleic acids
WO2021177996A1 (en) * 2020-03-02 2021-09-10 Northwestern University Fit-flares for detection of intracellular analytes in live cells
WO2021183485A1 (en) * 2020-03-09 2021-09-16 Emory University Heteromultivalent spherical nucleic acids and uses in therapeutic and diagnostic applications
WO2022183043A1 (en) * 2021-02-26 2022-09-01 Northwestern University Strategies to develop genome editing spherical nucleic acids (snas)
WO2022231730A2 (en) * 2021-03-22 2022-11-03 Northwestern University Synthetic strategy to polymerize protein into molecularly defined polymers
US20230031305A1 (en) * 2021-07-30 2023-02-02 10X Genomics, Inc. Compositions and methods for analysis using nucleic acid probes and blocking sequences
CN115671309B (zh) * 2021-07-30 2025-05-09 北京键凯科技股份有限公司 一种抗体-siRNA药物偶联物
CN116459217B (zh) * 2023-04-14 2024-07-23 大连理工大学 一种用于蛋白质递送的多级响应型聚合物囊泡的制备方法
CN117285013B (zh) * 2023-09-13 2025-11-18 中山大学 一种硒化镉量子点及其制备方法和应用

Family Cites Families (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4489055A (en) 1978-07-19 1984-12-18 N.V. Sopar S.A. Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
EP0366685B1 (en) 1987-06-24 1994-10-19 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
DE3738460A1 (de) 1987-11-12 1989-05-24 Max Planck Gesellschaft Modifizierte oligonukleotide
JPH03503894A (ja) 1988-03-25 1991-08-29 ユニバーシィティ　オブ　バージニア　アランミ　パテンツ　ファウンデイション オリゴヌクレオチド　ｎ‐アルキルホスホラミデート
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
DE69034150T2 (de) 1989-10-24 2005-08-25 Isis Pharmaceuticals, Inc., Carlsbad 2'-Modifizierte Oligonukleotide
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (es) 1990-05-11 1998-08-01 Microprobe Corp Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
JPH0874B2 (ja) 1990-07-27 1996-01-10 アイシス・ファーマシューティカルス・インコーポレーテッド 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
MY107332A (en) 1990-08-03 1995-11-30 Sterling Drug Inc Compounds and methods for inhibiting gene expression.
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
JPH06505704A (ja) 1990-09-20 1994-06-30 ギリアド　サイエンシズ，インコーポレイテッド 改変ヌクレオシド間結合
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US7223833B1 (en) 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
EP0538194B1 (de) 1991-10-17 1997-06-04 Novartis AG Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
PL172710B1 (pl) 1992-07-02 1997-11-28 Hybridon Inc Samostabilizujacy sie oligonukleotyd PL PL
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
CA2159631A1 (en) 1993-03-30 1994-10-13 Sanofi Acyclic nucleoside analogs and oligonucleotide sequences containing them
HU9501974D0 (en) 1993-03-31 1995-09-28 Sterling Winthrop Inc Oligonucleotides with amide linkages replacing phosphodiester linkages
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
ATE174600T1 (de) 1993-10-27 1999-01-15 Ribozyme Pharm Inc 2'-amido-und 2'-peptido-modifizierte oligonukleotide
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
US5912340A (en) 1995-10-04 1999-06-15 Epoch Pharmaceuticals, Inc. Selective binding complementary oligonucleotides
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6506564B1 (en) 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
EP0856579A1 (en) 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH An antisense oligonucleotide preparation method
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
WO1999027086A1 (en) 1997-11-25 1999-06-03 Brax Group Limited Chimeric antisense oligonucleotides against tnf-alpha and their uses
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US6080580A (en) 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
EP1072679A3 (en) 1999-07-20 2002-07-31 Agilent Technologies, Inc. (a Delaware corporation) Method of producing nucleic acid molecules with reduced secondary structure
JP2003516151A (ja) 1999-11-29 2003-05-13 エイブイアイ バイオファーマ， インコーポレイテッド 細菌１６Ｓおよび２３ＳｒＲＮＡに標的化された、荷電していないアンチセンスオリゴヌクレオチド、ならびにその使用
US20030181412A1 (en) 1999-12-21 2003-09-25 Ingeneus Corporation Method for modifying transcription and/or translation in an organism for therapeutic, prophylactic and/or analytic uses
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
DK1345959T3 (da) 2000-11-20 2011-09-05 Univ Illinois Membranscaffoldproteiner
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
EP2366406A1 (en) 2001-01-25 2011-09-21 ZymoGenetics, Inc. Method for treating psoriasis
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20090299045A1 (en) 2001-05-18 2009-12-03 Sirna Therapeutics, Inc. RNA Interference Mediated Inhibition Of Interleukin and Interleukin Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20060019917A1 (en) 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
WO2002096262A2 (en) 2001-05-25 2002-12-05 Northwestern University Non-alloying core shell nanoparticles
JP2005511761A (ja) 2001-07-10 2005-04-28 ノース・キャロライナ・ステイト・ユニヴァーシティ ナノ粒子送達ビヒクル
US6942972B2 (en) * 2001-10-24 2005-09-13 Beckman Coulter, Inc. Efficient synthesis of protein-oligonucleotide conjugates
AU2002343792A1 (en) 2001-11-28 2003-06-10 Center For Advanced Science And Technology Incubation, Ltd. siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
AU2002350332A1 (en) 2001-12-17 2003-06-30 Tao Chen Methods of parallel gene cloning and analysis
ATE556714T1 (de) 2002-02-01 2012-05-15 Life Technologies Corp Doppelsträngige oligonukleotide
US20040038303A1 (en) 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US7528116B2 (en) 2002-05-30 2009-05-05 Memorial Sloan Kettering Cancer Center Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
US20040023382A1 (en) 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of PPP3CB expression
DE10238298A1 (de) 2002-08-21 2004-03-04 Beiersdorf Ag Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2502649A1 (en) 2002-10-18 2004-04-29 Nucleonics Inc. Double-stranded rna structures and constructs, and methods for generating and using the same
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20040158051A1 (en) 2002-11-19 2004-08-12 Mihri Ozkan Mono and dual conjugation of nanostructures and methods of making and using thereof
GB0227738D0 (en) 2002-11-28 2003-01-08 Univ Liverpool Nanoparticle conjugates and method of production thereof
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
US20060116824A1 (en) 2004-12-01 2006-06-01 Ishikawa Muriel Y System and method for modulating a humoral immune response
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
EP2336778A1 (en) * 2004-03-24 2011-06-22 Oncotherapy Science, Inc. Compositions and methods for treating lung cancer
US20080274454A1 (en) 2004-04-07 2008-11-06 Mirkin Chad A Reversible and Chemically Programmable Micelle Assembly With Dna Block-Copolymer Amphiphiles
JP5398982B2 (ja) 2004-05-24 2014-01-29 ミダテック リミテッド Ｒｎａリガンドを含むナノ粒子
EP1773303A2 (en) 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
US20080113929A1 (en) * 2004-06-08 2008-05-15 Coley Pharmaceutical Gmbh Abasic Oligonucleotide as Carrier Platform for Antigen and Immunostimulatory Agonist and Antagonist
US20060008907A1 (en) 2004-06-09 2006-01-12 The Curators Of The University Of Missouri Control of gene expression via light activated RNA interference
WO2006044660A2 (en) 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
GT200600065A (es) 2005-02-14 2006-10-02 Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2007086881A2 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
WO2006124089A1 (en) 2005-05-12 2006-11-23 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Self-assembled nucleic acid nanoarrays and uses therefor
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
JP2009511023A (ja) 2005-10-06 2009-03-19 ユニバーシティー、オブ、デラウェア ハンチントン病の治療のためのｇに富むポリヌクレオチド
US20090221095A1 (en) 2005-10-13 2009-09-03 Northwestern University Colorimetric Screening of DNA Binding/Intercalating Agents with Gold Nanoparticle Probes
PL1957044T3 (pl) 2005-12-01 2013-11-29 Pronai Therapeutics Inc Amfoteryczny preparat liposomowy
WO2007067733A2 (en) 2005-12-09 2007-06-14 Massachusetts Institute Of Technology Compositions and methods to monitor rna delivery to cells
US20070148251A1 (en) 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices
WO2007089607A2 (en) 2006-01-26 2007-08-09 University Of Massachusetts Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
GB0607866D0 (en) * 2006-04-20 2006-05-31 Isis Innovation Nanostructures
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
EP2056794A4 (en) 2006-08-08 2012-12-26 Univ Texas MULTIPLE ADMINISTRATION OF ACTIVE SUBSTANCES
US20100099858A1 (en) 2006-09-28 2010-04-22 Mirkin Chad A Maximizing Oligonucleotide Loading on Gold Nanoparticle
EP2121987B1 (en) 2007-02-09 2012-06-13 Northwestern University Particles for detecting intracellular targets
CA2679586A1 (en) 2007-02-27 2008-10-23 Northwestern University Molecule attachment to nanoparticles
EP2118129A4 (en) 2007-03-01 2010-04-28 Life Technologies Corp ISOLATED PHOSPHOLIPID PROTEIN PARTICLES
US20080292545A1 (en) 2007-04-04 2008-11-27 Yuehe Lin Functionalized Encoded Apoferritin Nanoparticles and Processes for Making and Using Same
EP2160464B1 (en) 2007-05-30 2014-05-21 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
US8278043B2 (en) 2007-06-05 2012-10-02 Melica Hb Methods and materials related to grey alleles
WO2009012786A2 (en) 2007-07-23 2009-01-29 Aarhus Universitet Nanoparticle-mediated treatment for inflammatory diseases
US20110300154A1 (en) 2007-08-21 2011-12-08 Children's Medical Center Corporation Treatment of airway hyperreactivity
JP5710977B2 (ja) * 2007-11-05 2015-04-30 バルティック テクノロジー デヴェロプメント，リミテッド 抗ウイルス薬としての修飾塩基を含むオリゴヌクレオチドの使用
US9265729B2 (en) 2007-12-06 2016-02-23 The University Of Tokushima Nanofunctional silica particles and manufacturing method thereof
CN105903029A (zh) 2007-12-12 2016-08-31 大学健康网络 高密度脂蛋白样肽磷脂支架（“hpps”）纳米颗粒
EP2257313A2 (en) 2008-02-21 2010-12-08 University of Kentucky Research Foundation Ultra-small rnas as toll-like receptor-3 antagonists
RU2496482C2 (ru) 2008-03-05 2013-10-27 Бакстер Интернэшнл Инк. Композиции и способы для доставки лекарственных средств
EP2105145A1 (en) 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
EP2288336B8 (en) 2008-04-25 2017-03-22 Northwestern University Nanostructures suitable for sequestering cholesterol
WO2010014572A2 (en) 2008-07-28 2010-02-04 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 9 expression by antisense oligonucleotides
WO2010017154A2 (en) 2008-08-04 2010-02-11 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 3 expression by antisense oligonucleotides
US20100047188A1 (en) 2008-08-04 2010-02-25 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 8 expression by antisense oligonucleotides
JP2011530293A (ja) 2008-08-08 2011-12-22 イデラ ファーマシューティカルズ インコーポレイテッド アンチセンスオリゴヌクレオチドによる骨髄細胞分化初期応答遺伝子８８（ｍｙｄ８８）発現の調節
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
US8574582B2 (en) 2008-10-31 2013-11-05 Janssen Biotech, Inc. Methods for mediating fibrotic response
TW201021852A (en) 2008-11-17 2010-06-16 Enzon Pharmaceuticals Inc Releasable fusogenic lipids for nucleic acids delivery systems
EP2365803B1 (en) 2008-11-24 2017-11-01 Northwestern University Polyvalent rna-nanoparticle compositions
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
AU2010203474B2 (en) 2009-01-08 2015-11-19 Northwestern University Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
JP2012520085A (ja) 2009-03-13 2012-09-06 エーゲン、インコーポレイテッド 生物活性ｒｎａの送達のための組成物及び方法
CN102449170A (zh) 2009-04-15 2012-05-09 西北大学 寡核苷酸功能化的纳米颗粒的递送
WO2011017456A2 (en) 2009-08-04 2011-02-10 Northwestern University Localized delivery of nanoparticles for therapeutic and diagnostic applications
WO2011017690A2 (en) 2009-08-07 2011-02-10 Northwestern University Intracellular delivery of contrast agents with functionalized nanoparticles
EP2470656B1 (en) 2009-08-27 2015-05-06 Idera Pharmaceuticals, Inc. Composition for inhibiting gene expression and uses thereof
EP2473160A4 (en) 2009-09-01 2015-06-03 Univ Northwestern ADMINISTRATION OF THERAPEUTIC AGENTS WITH OLIGONUCLEOTIDE-MODIFIED NANOPARTICLES AS SUPPORT
US20120244230A1 (en) 2009-09-01 2012-09-27 Massachusetts Institute Of Technology Polyvalent polynucleotide nanoparticle conjugates as delivery vehicles for a chemotherapeutic agent
US20120288935A1 (en) * 2009-09-23 2012-11-15 Northwestern University "Click" Nanoparticle Conjugates
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US20110111974A1 (en) 2009-10-23 2011-05-12 Northwestern University Short Duplex Probes for Enhanced Target Hybridization
CA2779099C (en) 2009-10-30 2021-08-10 Northwestern University Templated nanoconjugates
EP3318248B1 (en) 2009-12-01 2019-04-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
US9138418B2 (en) 2009-12-09 2015-09-22 William Marsh Rice University Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles
WO2011079290A1 (en) 2009-12-24 2011-06-30 Northwestern University Oligonucleotide specific uptake of nanoconjugates
AU2011207563B2 (en) 2010-01-19 2016-03-10 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
EP2399608B1 (en) 2010-03-05 2020-07-08 Sebastian Fuchs Immunomodulating nanoparticulate composition for use in inhalation therapy
US20130101512A1 (en) 2010-03-12 2013-04-25 Chad A. Mirkin Crosslinked polynucleotide structure
CN102917690B (zh) 2010-03-19 2016-08-24 麻省理工学院 脂质囊泡组合物和使用方法
WO2011127405A1 (en) * 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Methods and compositions for enhanced delivery of compounds
CA3090304A1 (en) 2010-05-13 2011-11-17 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
US9549901B2 (en) 2010-09-03 2017-01-24 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
JP6027011B2 (ja) 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物
JP5813778B2 (ja) 2010-11-19 2015-11-17 イデラ ファーマシューティカルズ インコーポレイテッドＩｄｅｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トール様受容体に基づく免疫反応を調節するための免疫調節オリゴヌクレオチド（ｉｒｏ）化合物
KR101352342B1 (ko) * 2010-11-24 2014-02-17 서울대학교산학협력단 코어 물질과 쉘 물질 사이에 나노갭이 형성된 단일 나노입자 및 이의 제조방법
KR102043422B1 (ko) 2011-06-09 2019-11-11 큐알엔에이, 인크. 프라탁신 (fxn)에 대한 자연 안티센스 전사체의 저해에 의한 프라탁신 (fxn) 관련된 질환의 치료
WO2013012628A2 (en) 2011-07-15 2013-01-24 The University Of Georgia Research Foundation, Inc. Immune-stimulating photoactive hybrid nanoparticles
SI2734510T1 (sl) 2011-07-22 2019-05-31 Massachusetts Institute Of Technology Aktivatorji histon deacetilaz (HDACS) razreda I in njihove uporabe
AU2012308320C1 (en) 2011-09-14 2018-08-23 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds
AU2012308302A1 (en) 2011-09-14 2014-03-20 Northwestern University Nanoconjugates able to cross the blood-brain barrier
TW201321018A (zh) 2011-11-28 2013-06-01 Univ Kaohsiung Medical 多功能聚合物奈米粒子之醫藥用途
WO2013086207A1 (en) 2011-12-06 2013-06-13 The Ohio State University Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
JP6375289B2 (ja) 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
EP2852380A4 (en) 2012-05-23 2016-01-20 Univ Ohio State LIPID-COATED ALBUMIN NANOPARTICLE COMPOSITIONS AND METHOD FOR THE PREPARATION AND METHOD OF USE THEREOF
WO2014025795A1 (en) 2012-08-07 2014-02-13 Northeastern University Compositions for the delivery of rna and drugs into cells
AU2014215421A1 (en) 2013-02-05 2015-08-13 1Globe Health Institute Llc Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
US9617544B2 (en) 2013-04-11 2017-04-11 The Board Of Trustees Of The University Of Illinois Nanoparticle mediated delivery of siRNA
US10590412B2 (en) 2013-04-19 2020-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation nucleic acids through nonsense mediated decay
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
DK3077510T3 (da) 2013-12-02 2020-06-08 Ionis Pharmaceuticals Inc Antisense-forbindelser og anvendelser deraf
US10182988B2 (en) 2013-12-03 2019-01-22 Northwestern University Liposomal particles, methods of making same and uses thereof
EP3128008B1 (en) 2014-04-04 2024-05-29 Bioneer Corporation Double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
CN107074767A (zh) 2014-08-20 2017-08-18 西北大学 用于反义基因调节的生物相容的无限配位聚合物纳米颗粒–核酸缀合物
CR20170181A (es) 2014-10-06 2017-05-31 Exicure Inc Compuestos anti-tnf
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CA2973702A1 (en) 2015-01-14 2016-07-21 Exicure, Inc. Nucleic acid nanostructures with core motifs
WO2017011662A1 (en) 2015-07-14 2017-01-19 Exicure, Inc. Spherical nucleic acid (sna)-mediated delivery of lipid-complexes to cells
US10426842B2 (en) * 2015-07-15 2019-10-01 The Curators Of The University Of Missouri Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug
WO2017035278A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
SG11201905601VA (en) 2017-01-24 2019-08-27 Olipass Corp Scn9a antisense pain killer
WO2018152327A1 (en) 2017-02-15 2018-08-23 Northwestern University Enhancing stability and immunomodulatory activity of liposomal spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
WO2018213585A1 (en) 2017-05-17 2018-11-22 Northwestern University Conjugation of peptides to spherical nucleic acids (snas) using tracelless linkers
WO2019118883A1 (en) 2017-12-15 2019-06-20 Northwestern University Structure-function relationships in the development of immunotherapeutic agents
EP3810776A1 (en) 2018-06-22 2021-04-28 F. Hoffmann-La Roche AG Oligonucleotides for modulating scn9a expression

Also Published As

Publication number Publication date
JP6797108B2 (ja) 2020-12-09
EP3183007B1 (en) 2020-06-17
EP3183007A4 (en) 2018-01-10
JP2017527554A (ja) 2017-09-21
AU2024205692A1 (en) 2024-10-10
CN106794256A (zh) 2017-05-31
US20170232109A1 (en) 2017-08-17
US12264344B2 (en) 2025-04-01
EP3183007A1 (en) 2017-06-28
CA2958431A1 (en) 2016-02-25
AU2021201060A1 (en) 2021-03-11
WO2016028940A1 (en) 2016-02-25
AU2015305482B2 (en) 2021-04-01
AU2015305482A1 (en) 2017-03-02
CN106794256B (zh) 2021-04-30
CN113069551A (zh) 2021-07-06

Similar Documents

Publication Publication Date Title
MX2017002085A (es) Tratamientos con nanopartículas núcleo-corteza de proteína/oligonucleótido.
MX2022001105A (es) Anticuerpos anti tigit.
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
MX360041B (es) Composiciones y metodos para el cuidado personal.
CA160630S (en) Body groomer
PL3458074T3 (pl) KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA
ZA201608077B (en) Combination, composition, and method of administering the combination or composition to animals
PH12016501763B1 (en) Multispecific antibodies
AU362319S (en) Pet treat
WO2015073587A3 (en) Synthetic membrane-receiver complexes
AU356754S (en) Lid
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
EP3256110A4 (en) Compositions and methods of tumor treatment utilizing nanoparticles
AU352197S (en) Hitch step
CN106659716A8 (zh) 阿吡莫德组合物及其使用方法
TWD173859S (zh) 電連接器
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
TWD172410S (zh) 電連接器
MX2015016603A (es) Composiciones de corticosteroides.
PH12016502311A1 (en) Omega-3 analogues
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
PL3160509T3 (pl) Kompozycja przeciwnowotworowa na bazie kwasu hialuronowego i nieorganicznych nanocząsteczkach, metoda jej przygotowania i użycie
MX2015008947A (es) Nuevas composiciones antifungicas.
AU2014902893A0 (en) Probiotic composition, methods of production and methods of use